ArticleAntimicrobial agents and chemotherapy2020
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Treatment Options for Metallo-Beta-Lactamase-ProducingInternational journal of molecular sciences · 2026Review
- Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC medicinal chemistry · 2025Review
- Harder than Metal: Challenging Antimicrobial Resistance with Metallo-β-lactamase Inhibitors.Journal of medicinal chemistry · 2025Review
- Article
- Article
- β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Drug development concerning metallo-β-lactamases in gram-negative bacteria.Frontiers in microbiology · 2022Review
- Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-PositiveAntimicrobial agents and chemotherapy · 2021Article
- Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-ProducingAntimicrobial agents and chemotherapy · 2021Review
- Reply to Asempa et al., "The Ongoing Challenge with NDM-HarboringAntimicrobial agents and chemotherapy · 2021Article
- The Ongoing Challenge with NDM-HarboringAntimicrobial agents and chemotherapy · 2021Article
- Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.Infection and drug resistance · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.